at://
/
app.bsky.feed.post
/
3mnajsahtpc2b
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
PostEmbed
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC - ecancer
ecancer.org
Prof Tony Mok speaks to ecancer about the long-term follow-up from the phase 3 CROWN trial. It shows that lorlatinib continues to provide exceptional and durabl
